Edition:
United States

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

33,375.37ZAc
29 Apr 2016
Change (% chg)

473.00c (+1.43%)
Prev Close
33,075.00c
Open
32,834.00c
Day's High
33,588.00c
Day's Low
32,749.00c
Volume
1,143,351
Avg. Vol
1,299,094
52-wk High
39,097.00c
52-wk Low
23,364.00c

APNJ.J

Chart for APNJ.J

About

Aspen Pharmacare Holdings Limited is a South Africa-based pharmaceutical company. The Company through its subsidiaries manufactures branded and generic pharmaceutical products as well as infant milk nutritionals and consumer healthcare products in selected territories, operating primarily in the healthcare industry. The Company... (more)

Overall

Beta: 0.59
Market Cap(Mil.): R153,096.80
Shares Outstanding(Mil.): 456.35
Dividend: 216.00
Yield (%): 0.64

Financials

  APNJ.J Industry Sector
P/E (TTM): 25.27 34.64 45.44
EPS (TTM): 13.27 -- --
ROI: 9.09 13.05 12.52
ROE: 16.39 13.73 13.40
Search Stocks

UPDATE 1-Drugmakers ask South African government for extra price rise - Aspen CEO

JOHANNESBURG, March 3 South African pharmaceutical companies have asked the government to approve an extra increase in medicine prices this year to compensate for a weaker rand, Aspen Pharmacare's chief executive told Reuters on Thursday.

Mar 03 2016

South Africa's Aspen Pharmacare posts 14 pct rise in H1 profit

JOHANNESBURG, March 3 South Africa's Aspen Pharmacare Holdings reported a 14 percent rise in half-year profit on Thursday as revenue growth in most international markets offset a weak showing at home.

Mar 03 2016

BRIEF-Aspen Pharmacare H1 comparable normalised HEPS rises 21 pct

* Comparable NHEPS for six months ended 31 December 2015 was 640,9 cents, an increase of 21 pct

Mar 03 2016

BRIEF-Aspen Pharmacare sees comparable NHEPS for 6 mths ended Dec. 31 up 18-23 pct

* Sees comparable NHEPS for 6 mths ended Dec. 31 between 623.6 cents and 650.1 cents, up between 18 pct and 23 pct

Feb 23 2016

BRIEF-Aspen Pharmacare buys rights to hydroxyprogesterone caproate finished dose

* Acquired intellectual property and approved abbreviated new drug application in u.s. In respect of finished dose form of hydroxyprogesterone caproate Source text for Eikon: Further company coverage:

Feb 19 2016

BRIEF-Aspen buys rights to hydroxyprogesterone caproate injection

* JSE: APN - voluntary announcement - Aspen acquires the rights to hydroxyprogesterone caproate injection (hpc)

Dec 01 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$169.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks